The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market’s growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to further propel the diabetes medicines market.
Get Free Sample link @ https://www.omrglobal.com/request-sample/incretin-based-drugs-market
For instance, in October 2021, Glenmark launched drug in combination of various incretin based drug types including remogliflozin, vildagliptin, metformin fixed-dose combination (FDC) at an affordable cost for adults with type-2 diabetes. Among others, India is the first country to get access to this FDC drug. Glenmark had received an approval for the drug from the Drug Controller General of India (DCGI) for manufacturing and marketing back in September 2021. The new drug launched combines two or more active incretin based drugs in a single dosage form and can manage most of the pathophysiology in managing uncontrolled type-2 Diabetes. Further, in April 2019, Glenmark developed Remogliflozin, an oral anti-diabetic medicine that is deemed helpful in treating individuals with type-2 diabetes mellitus. Thus, increased product development in emerging countries along with rising healthcare expenditure will bolster the growth of the market.
A full report of Global Incretin Based Drugs Market available @ https://www.omrglobal.com/industry-reports/incretin-based-drugs-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Global Incretin Based Drugs Market Report Segment
By Drug Type
- Glucagon-like Peptide-1 Receptor Agonists
- Dipeptidyl Peptidase-4 Inhibitor
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Incretin Based Drugs Market Report Segment by Region
North America
- US
- Canada
Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East & Africa
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global incretin-based drugs market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/incretin-based-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
